Sign in or Register   Sign in or Register
  |  

Human Anti-CD22 Recombinant Antibody (CBXC-0817) (CBMAB-C1931-CQ)

This product is a recombinant human antibody that recognizes CD22. The antibody CBXC-0817 can be used for immunoassay techniques such as: FC.
See all CD22 antibodies

Summary

Host Animal
Human
Specificity
Human
Clone
CBXC-0817
Antibody Isotype
IgG1
Application
FC

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
Buffer containing stabilizer
Preservative
0.05% sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
CD22 Molecule
Introduction
CD22 (CD22 Molecule) is a Protein Coding gene. Diseases associated with CD22 include Refractory Hematologic Cancer and Refractory Hairy Cell Leukemia. Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System. Gene Ontology (GO) annotations related to this gene include carbohydrate binding. An important paralog of this gene is SIGLEC1.
Entrez Gene ID
UniProt ID
Alternative Names
CD22 Molecule; CD22 Antigen; Sialic Acid-Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2;
Function
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
Biological Process
B cell activation Source: ARUK-UCL
Cell adhesion Source: ProtInc
Negative regulation of B cell receptor signaling pathway Source: ARUK-UCL
Negative regulation of calcium-mediated signaling Source: ARUK-UCL
Negative regulation of immunoglobulin production Source: ARUK-UCL
Regulation of B cell proliferation Source: ARUK-UCL
Regulation of endocytosis Source: ARUK-UCL
Regulation of immune response Source: ARUK-UCL
Cellular Location
Cell membrane
Topology
Extracellular: 20-687
Helical: 688-706
Cytoplasmic: 707-847
PTM
Phosphorylation of Tyr-762, Tyr-807 and Tyr-822 are involved in binding to SYK, GRB2 and SYK, respectively. Phosphorylation of Tyr-842 is involved in binding to SYK, PLCG2 and PIK3R1/PIK3R2.
Phosphorylated on tyrosine residues by LYN.

Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., ... & Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 27(8), 1419-1431.

Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L., Steimle, B., ... & Dropulić, B. (2021). Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 13(586).

Lanza, F., Maffini, E., Rondoni, M., Massari, E., Faini, A. C., & Malavasi, F. (2020). CD22 expression in b-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults. Cancers, 12(2), 303.

Nyesiga, B., & El-Schich, Z. (2020). CD22 (CD22 molecule). Atlas of Genetics and Cytogenetics in Oncology and Haematology.

Wasim, L., Buhari, F. H. M., Yoganathan, M., Sicard, T., Ereño-Orbea, J., Julien, J. P., & Treanor, B. (2019). N-linked glycosylation regulates CD22 organization and function. Frontiers in immunology, 10, 699.

Clark, E. A., & Giltiay, N. V. (2018). CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Frontiers in immunology, 9, 2235.

Sheikh, A. A. D., Akatsu, C., Imamura, A., Abdu-Allah, H. H., Takematsu, H., Ando, H., ... & Tsubata, T. (2018). Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2, 6 sialic acid-dependent and-independent interactions. Biochemical and biophysical research communications, 495(1), 854-859.

Pirosa, M. C., Leotta, S., Cupri, A., Stella, S., Martino, E. A., Scalise, L., ... & Milone, G. (2018). Long-term molecular remission achieved by antibody anti-cd22 and ponatinib in a patient affected by ph’+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: A case report. Chemotherapy, 63(4), 220-224.

Ereño-Orbea, J., Sicard, T., Cui, H., Mazhab-Jafari, M. T., Benlekbir, S., Guarné, A., ... & Julien, J. P. (2017). Molecular basis of human CD22 function and therapeutic targeting. Nature communications, 8(1), 1-11.

Peng, W., & Paulson, J. C. (2017). CD22 ligands on a natural N-glycan scaffold efficiently deliver toxins to B-lymphoma cells. Journal of the American Chemical Society, 139(36), 12450-12458.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human Anti-CD22 Recombinant Antibody (CBXC-0817)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare